• Bookmark and Share

PARTICIPATE IN A RESEARCH STUDY

Last Updated on Tuesday, October 07, 2014

Clinical and other research trials are important to advance scientific knowledge about hypertensive disorders of pregnancy.

Periodically, the Preeclampsia Foundation makes arrangements with investigators to make enrollment information available about their studies. The following preeclampsia research trials have been approved by Institutional Review Boards. If you are interested in participating in one of the following studies, please contact the primary study investigator directly to inquire about enrollment. Listing of these studies on this site does not constitute an endorsement or recommendation by the Preeclampsia Foundation.

Preeclampsia survivors and those at risk for these pregnancy complications should seek to understand the benefits, alternatives and risks of participating in any research study, including those intended to study prevention or therapeutic interventions. Please know that the choice to participate in any research study is up to you.


Putting Together the Preeclampsia Puzzle


We are working with external investigators to analyze data from The Preeclampsia Registry to answer a variety of research questions.

Have you or any of your family members EVER had preeclampsia or high blood pressure in pregnancy? 

Please consider enrolling in The Preeclampsia Registry at www.PreeclampsiaRegistry.org. Preeclampsia and related hypertensive disorders of pregnancy are life-threatening to the mother and her unborn baby. Your story, medical and pregnancy history, and ongoing health reporting will help scientists unravel all the pieces of this puzzle.

Our goal is to have well over 10,000 participants including women directly affected, their sisters, and even friends who were not affected (to serve as “controls”). To learn more or enroll, go to www.PreeclampsiaRegistry.org. If you have questions, please email Registry@Preeclampsia.org.


Other Study Recruitments 

Research Study: PRESERVE-1

You may be eligible for this study if you are:

  • 16 years of age or older and
  • 24 to 28 weeks pregnant with a recent diagnosis of preeclampsia or superimposed preeclampsia and
  • If you are being treated at one of the study locations listed below

This is a study of a medication which is Antithrombin (Recombinant).  Antithrombin (Recombinant) may be useful in the treatment of early onset preeclampsia as women with this condition generally have lower than normal antithrombin levels. This study will assess if Antithrombin (Recombinant) can increase the time that your baby stays in the womb, decrease the problems that you may experience or improve the health and well-being of your baby.

Participation in this study will involve gathering your medical history, physical exams, blood and urine collection, taking the study medication, and monitoring for side effects under observation by a physician. Some participants will receive the medication and some participants will receive a placebo, which is a saline solution without active ingredients. Your baby will also be followed after delivery.

If you are interested in participating or learning more please visit www.clinicaltrials.gov/ct2/show/NCT02059135 or www.preserve-1.org.

 

In addition, ClinicalTrials.gov is a registry of most federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. 

Investigators interested in our Study Participant Recruitment Services should contact the Preeclampsia Foundation at info@preeclampsia.org

The Preeclampsia Registry

    The Preeclampsia Registry is a "Living Database" bringing together those affected, their family members, and researchers to advance knowledge and discover preventions and treatments for preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy.

Research Resources

Research Funding

 

Other Resources

JOIN OUR MAILING LIST. We respect your privacy.